[Epistaxis in patients with hereditary hemorrhagic teleangiectasia]
- PMID: 17345820
- DOI: 10.2298/mpns0610443j
[Epistaxis in patients with hereditary hemorrhagic teleangiectasia]
Abstract
Introduction: Spontaneous recurrent epistaxis is the most common clinical manifestation of hereditary hemorrhagic teleangiectasia (HHT). It occurs in more than 90% of HHT patients and is the most distressing symptom. Nasal teleangiectasias tend to increase with age both in size and number, so epistaxis is heavier and more frequent. For patients with mild to moderate disease, there are many adequate treatment options. For those with severe disease, most treatments offer just a hemorrhage-free interval. Experienced otorhinolaryngologists who treat epistaxis in these patients often use the adage "to do as little as possible for as long as possible".
Management of acute epistaxis: The recommendations for the management of acute epistaxis include: compression, use of topical antifibrinolytics, laser therapy, argon plasma coagulation therapy, fibrin sealant spray or gelatin sponge soaked in adrenaline. In cases of heavy acute epistaxis, an epistaxis balloon combined with artery ligation and/or embolization is the most effective treatment. Nasal packing and electrocauterisation should be avoided to prevent further trauma to the blood vessels.
Treatment of recurrent epistaxis: Management of recurrent epistaxis includes topical application of laser energy (argon, Nd:YAG, KTP/532 and diode, not CO2), argon plasma coagulation in combination with 0.1% estriol ointment, caustics, antifibrinolytics, bleomycin and sclerosing substances. Systemic estrogen-progesterone at doses used for oral contraception may eliminate bleeding in women with heavy epistaxis. Systemic antifibrinolitics (used with extreme precaution) and septal dermoplasty give good results. The only method which successfully and permanently solves the problem of severe refractory epistaxis in hereditary hemorrhagic teleangiectasia is closure of the nasal cavities.
Similar articles
-
Combined therapy for epistaxis by hereditary hemorrhagic teleangiectasia: A 3-year follow up study on 45 patients.J Craniomaxillofac Surg. 2017 Aug;45(8):1179-1182. doi: 10.1016/j.jcms.2017.05.018. Epub 2017 May 24. J Craniomaxillofac Surg. 2017. PMID: 28615135
-
Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.Lasers Surg Med. 2020 Apr;52(4):293-300. doi: 10.1002/lsm.23147. Epub 2019 Aug 22. Lasers Surg Med. 2020. PMID: 31441079 Free PMC article.
-
Clinical Practice Guideline: Nosebleed (Epistaxis).Otolaryngol Head Neck Surg. 2020 Jan;162(1_suppl):S1-S38. doi: 10.1177/0194599819890327. Otolaryngol Head Neck Surg. 2020. PMID: 31910111
-
Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary.Otolaryngol Head Neck Surg. 2020 Jan;162(1):8-25. doi: 10.1177/0194599819889955. Otolaryngol Head Neck Surg. 2020. PMID: 31910122 Review.
-
A treatment algorithm for the management of epistaxis in hereditary hemorrhagic telangiectasia.Am J Rhinol. 1999 Jul-Aug;13(4):319-22. doi: 10.2500/105065899782102890. Am J Rhinol. 1999. PMID: 10485021
Cited by
-
Intensity-modulated radiotherapy for a rendu-osler-weber disease patient with recurrent severe epistaxis: a case report.Case Rep Med. 2010;2010:321835. doi: 10.1155/2010/321835. Epub 2010 Mar 28. Case Rep Med. 2010. PMID: 20368796 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Research Materials